Ashwin Kishtagari, MBBS, is Assistant Professor of Medicine in the division of hematology and oncology at Vanderbilt ...

Karyopharm is hoping to broaden the label for its first-in-class blood cancer therapy Xpovio to include myelofibrosis, even though the drug hit only one of two primary endpoints in a pivotal study. In ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Anemia in myelofibrosis significantly affects survival and quality of life, with severe anemia reducing median survival fourfold compared to non-anemic patients. Transfusion dependency in ...

John Mascarenhas, MD, describes how the SOHO 2025 MPN session highlighted the four approved JAK inhibitors — ruxolitinib, momelotinib, pacritinib, and fedratinib — allowing for personalized treatment ...

Dr. Prithviraj Bose discussed the current treatment landscape for myeloproliferative neoplasms, a group of rare blood cancers; he focused on myelofibrosis. Dr. Prithviraj Bose, a professor in the ...

Patients saw a clinical benefit with luspatercept, however it was not statistically significant. Topline data were announced from a phase 3 trial evaluating luspatercept-aamt plus Janus kinase 2 ...

Panelists discuss how evolving insights into myelofibrosis—driven by molecular profiling, risk-adaptive therapy, and emerging treatments—are reshaping clinical practice toward more personalized care, ...

Vonjo is a medicine called a kinase inhibitor that is used to treat certain types of a blood disorder called myelofibrosis. Myelofibrosis is a type of blood cancer that causes scarring (fibrosis) in ...

Primary myelofibrosis (PMF) is a rare bone marrow disorder that affects the production of blood cells. It causes scarring, or fibrosis, in the bone marrow, which reduces the body’s ability to produce ...

A subset of patients with myeloproliferative neoplasms (MPNs) -- clonal disorders of hematopoietic stem cells that include polycythemia vera and essential thrombocythemia, as well as primary ...